Lundbeck CSO: It will have a huge impact
For the first time ever, Lundbeck has received official word that its antidepressant Brintellix improves cognitive functions. Lundbeck’s science chief spoke to MedWatch about the importance of the seal of approval.
BY BENJAMIN WERNER CHRISTENSEN & STEFAN SINGH KAILAY
Lundbeck might be on the verge of achieving something with one of its antidepressants that has never been achieved before.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
"I haven’t spoken to anyone myself"
For abonnenter
R&D chief: Brintellix data are highly significant
For abonnenter
“This is not a sausage factory”
For abonnenter
